康艾注射液辅助紫杉醇、卡铂治疗三阴性乳腺癌的临床疗效及对患者炎症因子的影响

高阳; 刘银凤; 张静; 李燕莉; 吴旻骅; 李婷

doi:10.14009/j.issn.1672-2124.2022.11.008

您当前的位置：

首页 >

文章列表页 >

康艾注射液辅助紫杉醇、卡铂治疗三阴性乳腺癌的临床疗效及对患者炎症因子的影响

论著 | 更新时间：2023-04-16

- 康艾注射液辅助紫杉醇、卡铂治疗三阴性乳腺癌的临床疗效及对患者炎症因子的影响
- Clinical Efficacy of Kang’ai Injection Combined with Paclitaxel and Carboplatin in the Treatment of Triple-Negative Breast Cancer and Its Effects on Inflammatory Factors
- 中国医院用药评价与分析 2022年第11期页码：1318-1321
- 作者机构：
  
  1. 秦皇岛市第一医院重症医学科
  2. 秦皇岛市第一医院乳腺外科
  3. 秦皇岛市第一医院普通外科
  4. 宁波市医疗中心李惠利东部医院乳腺外科
- 作者简介：
- 基金信息：
  
  浙江省医药卫生科技计划项目（No.2018KY724）
- DOI：10.14009/j.issn.1672-2124.2022.11.008
  中图分类号： R737.9
- 纸质出版日期：2022，
扫描看全文
高阳, 刘银凤, 张静, 等. 康艾注射液辅助紫杉醇、卡铂治疗三阴性乳腺癌的临床疗效及对患者炎症因子的影响[J]. 中国医院用药评价与分析, 2022,(11):1318-1321.

GAO Yang, LIU Yinfeng, ZHANG Jing, et al. Clinical Efficacy of Kang’ai Injection Combined with Paclitaxel and Carboplatin in the Treatment of Triple-Negative Breast Cancer and Its Effects on Inflammatory Factors[J]. 2022,(11):1318-1321.
高阳, 刘银凤, 张静, 等. 康艾注射液辅助紫杉醇、卡铂治疗三阴性乳腺癌的临床疗效及对患者炎症因子的影响[J]. 中国医院用药评价与分析, 2022,(11):1318-1321. DOI： 10.14009/j.issn.1672-2124.2022.11.008.

GAO Yang, LIU Yinfeng, ZHANG Jing, et al. Clinical Efficacy of Kang’ai Injection Combined with Paclitaxel and Carboplatin in the Treatment of Triple-Negative Breast Cancer and Its Effects on Inflammatory Factors[J]. 2022,(11):1318-1321. DOI： 10.14009/j.issn.1672-2124.2022.11.008.

摘要

目的：探讨康艾注射液辅助紫杉醇、卡铂治疗三阴性乳腺癌的临床疗效及对患者炎症因子的影响。方法：通过随机数字表法将2019年5月至2021年5月秦皇岛市第一医院收治的84例三阴性乳腺癌患者分为对照组与治疗组（每组42例）。对照组患者给予紫杉醇、卡铂方案治疗，治疗组患者采用康艾注射液辅助紫杉醇、卡铂治疗。对比两组患者治疗前后肿瘤标志物[癌胚抗原（CEA）、糖类抗原153（CA153）和糖类抗原125（CA125）]水平、免疫功能（CD3

、CD4

、CD8

和CD4

/CD8

）、生活质量精简量表（QOL-BREF）评分及血清炎症因子[C反应蛋白（CRP）、肿瘤坏死因子α（TNF-α）和白细胞介素6（IL-6）]水平，记录两组患者的临床疗效和不良反应。结果：治疗组患者的治疗总有效率高于对照组[92.86%（39/42）vs. 73.81%（31/42）]

差异有统计学意义（P=0.019）。治疗后，两组患者各项肿瘤标志物水平均显著降低，且治疗组患者CEA、CA153和CA125水平明显低于对照组，差异均有统计学意义（P＜0.05）。与治疗前相比，对照组与治疗组患者治疗后的CD3

、CD4

及CD4

/CD8

水平升高，CD8

水平降低；且相比于对照组，治疗组患者治疗后的CD3

、CD4

及CD4

/CD8

水平更高，CD8

水平更低，差异均有统计学意义（P＜0.05）。与治疗前相比，对照组与治疗组患者治疗后的QOL-BREF评分升高，且治疗组患者治疗后的QOL-BREF评分高于对照组，差异均有统计学意义（P＜0.05）。治疗后，两组患者血清炎症因子水平均显著降低；且相比于对照组，治疗组患者治疗后的CRP、TNF-α和IL-6水平更低，差异均有统计学意义（P＜0.05）。治疗组患者的不良反应发生率为7.14%（3/42）

低于对照组的23.81%（10/42）

差异有统计学意义（P=0.035）。结论：针对三阴性乳腺癌患者采用康艾注射液辅助紫杉醇、卡铂治疗能取得较理想的临床疗效，不但能降低肿瘤标志物和炎症因子水平，还能改善免疫功能，提高患者生活质量，减少不良反应。

Abstract

OBJECTIVE: To probe into the clinical efficacy of Kang’ai injection combined with paclitaxel and carboplatin in the treatment of triple-negative breast cancer and its effects on inflammatory factors. METHODS: Eighty-four triple-negative breast cancer patients admitted into the First Hospital of Qinhuangdao from May 2019 to May 2021 were extracted to be divided into the control group and the treatment group via the random number table

with 42 cases in each group. The control group was treated with paclitaxel and carboplatin regimen

while the treatment group received Kang’ai injection combined with paclitaxel and carboplatin. The levels of tumor markers [carcinoembryonic antigen（CEA）

carbohydrate antigen 153（CA153）

carbohydrate antigen 125（CA125）]

immune function（CD3

CD4

CD8

CD4

/CD8

）

QOL-BREF score

serum inflammatory factors [C-reactive protein（CRP）

tumor necrosis factor-α（TNF-α）

interleukin-6（IL-6）] of two groups were compared

and the clinical efficacy and adverse drug reactions were recorded. RESULTS: The total effective rate of treatment group was higher than that of control group [92.86%（39/42） vs. 73.81%（31/42）]

the difference was statistically significant（P=0.019）. After treatment

the levels of tumor markers in two groups decreased significantly

and the levels of CEA

CA153 and CA125 in the treatment group were significantly lower than those in the control group

the differences were statistically significant（P

0.05）. Compared with before treatment

CD3

CD4

and CD4

/CD8

in two groups increased

and CD8

decreased after treatment; compared with the control group

CD3

CD4

and CD4

/CD8

in the treatment group were higher

and CD8

was lower after treatment

the differences were statistically significant（P

0.05）. Compared with before treatment

the QOL-BREF score of two groups increased after treatment

and the QOL-BREF score of the treatment group was higher than that of the control group after treatment

the differences were statistically significant（P

0.05）. After treatment

the levels of serum inflammatory factors in two groups decreased significantly; compared with the control group

the levels of CRP

TNF-α and IL-6 in the treatment group were lower after treatment

the differences were statistically significant（P

0.05）. The incidence of adverse drug reactions in the treatment group was 7.14%（3/42）

lower than 23.81%（10/42） in the control group

the difference was statistically significant（P=0.035）. CONCLUSIONS: The clinical efficacy of Kang’ai injection combined with paclitaxel and carboplatin in the treatment of triple-negative breast cancer is significant

which can not only reduce the levels of tumor markers and inflammatory factors

but improve the immune function and patients’ quality of life with few adverse drug reactions.

关键词

康艾注射液紫杉醇卡铂方案三阴性乳腺癌临床疗效炎症因子

Keywords

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

小儿喘咳液治疗小儿呼吸道合胞病毒肺炎的临床研究

柴芍胃康汤联合四联疗法治疗肝胃气滞证Hp阳性慢性萎缩性胃炎的疗效观察

中药注射剂联合常规方案治疗黄疸型肝炎的网状Meta分析

免疫联合抗血管治疗对比免疫单药治疗用于晚期非小细胞肺癌患者的单中心数据分析

参芪补肺汤加减联合孟鲁司特钠治疗非小细胞肺癌术后慢性咳嗽的临床研究